Mirabegron: The most promising adipose tissue beiging agent

Area of Science:

• Metabolic Research
• Pharmacology
• Obesity Studies

Background:

• Obesity epidemic driven by white adipose tissue (WAT) accumulation.
• Adipose tissue (AT) beiging, induced by cold exposure, exercise, or beta-3 adrenergic receptor (β3AR) agonists, is a potential therapeutic strategy.
• The role of AT beiging in treating metabolic disorders like obesity and type 2 diabetes (T2D) requires further exploration.

Purpose of the Study:

• To review recent research on mirabegron, a β3AR agonist, for stimulating AT beiging.
• To compare mirabegron's effects with intermittent cold exposure (CE) and exercise-induced beiging.
• To assess the metabolic benefits of mirabegron in lean and obese individuals.

Main Methods:

• Review of in vivo animal and clinical studies on mirabegron.
• Comparison of mirabegron-induced beiging with CE and exercise-induced beiging.
• Analysis of mirabegron's effects on circulating adipokines, glucose metabolism, and lipid droplet size.

Main Results:

• Mirabegron effectively induces beiging in subcutaneous/inguinal WAT at optimal doses without adverse cardiovascular effects.
• Mirabegron administration positively impacts circulating adipokines, glucose metabolism, and lipid droplet size.
• Mirabegron demonstrates outcomes similar to intermittent CE and more direct evidence of beiging than exercise.

Conclusions:

• Mirabegron is a promising and safe β3AR agonist for metabolic disorder treatment.
• Mirabegron offers potential therapeutic benefits for both lean and obese individuals.
• Further research on mirabegron's synergistic effects with diet and exercise is warranted.